Сравнение

Amycretin vs. CagriSema

Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.

Идентичность

Категория

Метаболизм

Номер CAS

нет данных

Молекулярная масса

нет данных

Период полувыведения

нет данных

Последовательность

нет данных

Механизм действия

Amycretin

Amycretin activates both the GLP-1 and the amylin receptor in a single molecule. Both pathways independently suppress appetite and food intake — the combination is intended to amplify the effect beyond the GLP-1 axis alone.

CagriSema

CagriSema combines two satiety pathways in one weekly injection: the amylin analogue cagrilintide and the GLP-1 agonist semaglutide. Both suppress appetite and food intake — together more than either component alone.

Доказательная база

Наивысшая доказательность

РКИ на людях

Исследования

из них на людях

Зафиксированные эффекты

Открытые противоречия

Задокументированные нежелательные явления

Правовой статус

Country	Amycretin	CagriSema
Германия	Не одобрено	Не одобрено
США	Не одобрено	Не одобрено

Полные записи

Frequently asked questions

What is the difference between Amycretin and CagriSema?: Amycretin is classified as "Метаболизм", while CagriSema is classified as "Метаболизм". Amycretin: Amycretin is a unimolecular GLP-1 and amylin receptor agonist from Novo Nordisk — in development both as a once-weekly subcutaneous and a once-daily oral form for obesity and type 2 diabetes. CagriSema: CagriSema is a fixed-dose combination of the amylin analogue cagrilintide and the GLP-1 agonist semaglutide (Novo Nordisk), in late-stage development for obesity and type 2 diabetes. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Amycretin or CagriSema?: The highest available evidence level is "РКИ на людях" for Amycretin and "РКИ на людях" for CagriSema. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Amycretin and CagriSema in Germany and the United States?: Германия: Amycretin — Не одобрено, CagriSema — Не одобрено. США: Amycretin — Не одобрено, CagriSema — Не одобрено. These are factual summaries with source and review date on the individual pages.

Country

Amycretin

CagriSema

Германия

Не одобрено

США

Не одобрено

Frequently asked questions

What is the difference between Amycretin and CagriSema?

Amycretin is classified as "Метаболизм", while CagriSema is classified as "Метаболизм". Amycretin: Amycretin is a unimolecular GLP-1 and amylin receptor agonist from Novo Nordisk — in development both as a once-weekly subcutaneous and a once-daily oral form for obesity and type 2 diabetes. CagriSema: CagriSema is a fixed-dose combination of the amylin analogue cagrilintide and the GLP-1 agonist semaglutide (Novo Nordisk), in late-stage development for obesity and type 2 diabetes. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Amycretin or CagriSema?

The highest available evidence level is "РКИ на людях" for Amycretin and "РКИ на людях" for CagriSema. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Amycretin and CagriSema in Germany and the United States?

Германия: Amycretin — Не одобрено, CagriSema — Не одобрено. США: Amycretin — Не одобрено, CagriSema — Не одобрено. These are factual summaries with source and review date on the individual pages.